Recent Articles from GlobeNewswire

NEWPORT NEWS, Va., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jim Ledbetter, President and COO of Drucker + Falk will retire on December 31, 2025. Chief Financial Officer Guy Buck has been promoted to President effective January 1, 2026, ensuring a smooth transition.

PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive.

New capabilities strengthen cross-platform campaign reporting suite; CCR rebranded as Cross-Platform Campaign Results

Recognized for its approach to protecting AI-native software development in the AI and Machine Learning: Security category

ST. PETERSBURG, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Raymond James Investment Management, a global asset management company with $118.5 billion in assets and a wholly-owned subsidiary of Raymond James, has named Jeff Ringdahl as President, effective January 5. In this role, Mr. Ringdahl will lead the growth strategy and direction of the business, overseeing key initiatives and expansion opportunities.

[New Modern Ethical Leadership Ecosystem Helps Executives and Organizations Rebuild Integrity as Their Greatest Competitive Advantage]

Making it easier and faster to acquire leading telematics solutions

SAN JOSE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Today, Zoom Communications, Inc. (NASDAQ: ZM) unveiled the next evolution of its agentic AI solution, Zoom AI Companion 3.0, including new AI-first capabilities for personal workflows (beta), agentic AI features for Zoom Docs (coming soon), and a new web interface with expanded context to help users uncover insights, optimize their day, and uplevel their work.

MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, is proud to announce that the Belgium Ministry of Health (MOH) has approved its Clinical Trial Application for YntraDose® in the treatment of unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC). This authorization follows the recent approvals from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Italian Ministry of Health.

AI-Based Remote Monitoring, Remote Guarding, and Video Surveillance Power to Become Standardized Security Across the Operator’s Multiple Lots

Key milestones include the launch of FormAssembly’s agentic AI-enabled Atlas platform, a redesigned connector architecture, and enhancements to payments, e-signature, and document generation

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SPR announced that it has reached 50,000 implants of the SPRINT® PNS System, a significant milestone recognizing the impact of treatment for patients with 60-day peripheral nerve stimulation (PNS) treatment for pain. The rapid growth from 30,000 to 50,000 implants in just over a year reflects the adoption of SPRINT PNS as an approach for various types of pain throughout the body.

ENGLEWOOD, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuel and chemicals, and carbon management, today announced a strategic leadership transition designed to position the company for continued growth and innovation. Effective December 9, 2025, Dr. Paul Bloom has been appointed President of Gevo, Inc. and a director on Gevo’s Board of Directors. Gevo’s long-standing Chief Executive Officer and board member, Dr. Patrick Gruber, has assumed the role of Executive Chair of the Board. Board Chairman William H. Baum has moved into the role of lead independent director. As part of the succession plan, Dr. Gruber will continue as Chief Executive Officer until his retirement on April 1, 2026, at which time Dr. Bloom will succeed Dr. Gruber as Chief Executive Officer.

Funding to Support Development of AI & Advanced Manufacturing Gigafactory Initiative

Visionary and transformative leader to drive Tenable’s next phase of AI and platform innovation

Canine Competitors Shine as Thousands Vie for the Title of National Champion

CHICAGO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, kicked off a year-long celebration of its 175th anniversary of the YMCA in America commemorating more than a century and a half of service, innovation, and community impact. Since the establishment of the first United States-based YMCA in Boston in 1851, the Y has grown into one of the nation’s most influential and enduring nonprofit organizations, building connection and belonging in more than 10,000 communities.

Enhancements to the Nutanix Cloud Platform empower customers to maintain security, control, and resilience across distributed environments

LONG BEACH, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) announced today that the Company’s executives will be participating in the following events in January 2026:

Greenwich, CT and Cleveland, OH, Dec. 15, 2025 (GLOBE NEWSWIRE) -- A&M Capital, a multi-strategy private equity investment firm, and Asurint (the “Company”), an industry-leading provider of background screening solutions, announced today that Asurint has been acquired by A&M Capital Partners (“AMCP”), A&M Capital's investment strategy focused on middle-market control transactions in North America.

SAN MATEO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Freshworks Inc. (NASDAQ: FRSH) has signed a definitive agreement to acquire FireHydrant, a provider of AI-powered Incident Management software. The combination will bring together Freshservice’s IT Service Management (ITSM) and FireHydrant’s core IT Operations Management (ITOM) as a unified AI-native ServiceOps solution designed to simplify operations, proactively prevent disruptions, and ensure exceptional IT service reliability.

Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100

The third edition shows how structured, centrally managed email signatures strengthen brand consistency, compliance, and trust across every message sent

Miami, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Hunton Andrews Kurth LLP is pleased to welcome litigation and employment partner Carol C. Lumpkin and litigation partner Shawn Hogue, who have joined the firm in Miami.

The newly-revealed ‘Remora’ mission validated key Starfish software for autonomous satellite guidance and showcased Impulse’s precise maneuvering capabilities

Compass UOL recognized as Consulting Partner of the Year LATAM winner, one of many AWS Partners around the globe that help their customers drive innovation

New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits.

PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) --

SYDNEY, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Brazilian Rare Earths Limited (ASX: BRE / OTCQX: BRELY) (‘BRE’) is pleased to report the results of the Scoping Feasibility Study for its 100%-owned Amargosa Bauxite-Gallium Project (Amargosa, or the Project) in Bahia, Brazil.

New Survey Finds Wide Support for Preserving the Right to Pay in Cash

LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares.

DALLAS, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced an increase in the dividend rate on its Variable Rate Series A Perpetual Preferred Stock (the “SATA Stock”), raising the annual dividend rate to 12.25%, up from 12.00%.

CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to announce a project with Carver Pump Company (Carver Pump), a leading U.S. manufacturer of mission-critical pumps for the U.S. Navy, to accelerate the production of critical long lead time titanium components for naval shipbuilding.

SAN JOSE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- H2O America today announced that Eric W. Thornburg will retire as non-executive chair of the board of directors, effective Jan. 31, 2026. Mr. Thornburg has served the company with distinction for many years, including as chair, president, and CEO, and most recently as non-executive chair of the board. His leadership has been instrumental in shaping H2O America’s mission and its commitment to delivering high-quality, reliable water service to communities across the region.

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Namib Minerals Ltd. (“Namib” or the “Company”) today provided an operational update highlighting improving stability and cost performance across its producing asset as the Company approaches financial year-end.

SINGAPORE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BGIN BLOCKCHAIN LIMITED (“BGIN” or the “Company”; NASDAQ: BGIN), a digital asset technology company with proprietary cryptocurrency mining technologies and a manufacturer of cryptocurrency mining hardware, today announced the appointment of MaloneBailey, LLP (“MaloneBailey”) as the Company’s independent registered public accounting firm, effective December 12, 2025, replacing ZH CPA, LLC.

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

MONTRÉAL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV: CDPR) (OTCQB: GPPRF) (FRA: N8HP) (BVL:CDPR) (“CDPR” or the “Company”) is pleased to announce the formalization of its surface use agreement with the Community of Quiulacocha. The agreement was signed on December 11, 2025. This agreement reinforces CDPR’s long standing collaborative framework with the community and strengthens the company’s social license to operate, underscoring the constructive relationship that has supported the Quiulacocha Tailings Project over time.

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that its wholly-owned subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO to execute manufacture of its ALA-002 drug substance.

RESTON, Va., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Regula, a global developer of identity verification (IDV) solutions and forensic devices, published a new summary of insights from major global research sources, revealing how identity fraud accelerated across consumers, businesses, and public institutions throughout 2025. The findings reveal a clear pattern: AI-driven attacks have become increasingly sophisticated, credential exposure has reached record levels, and digital trust has eroded across the ecosystem.

The design of the “Helios” planar coil stellarator power plant demonstrates a uniquely practical commercial fusion architecture, enabling scalable manufacturing and construction, efficient maintenance, a high capacity factor, and competitive economics 

Tel Aviv, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, which recently began expanding into the global homeland security sector through advanced AI-driven solutions, today announced that its wholly owned subsidiary, KeepZone AI Inc., (“KeepZone”), has signed an exclusive distribution agreement with Zorronet Ltd. (”Zorronet”), an innovative Israeli deep-tech company specializing in autonomous AI-driven security platform, which is a subsidiary of Water.io,and is majority-owned by Star 26 Capital Inc., which is subject to a pending acquisition by Nukkleus Inc. (Nasdaq: NUKK).

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.

HIGHLIGHTS

WEST PALM BEACH, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced its dividend for the quarter ending December 31, 2025.

Purpose-built for compliance, complexity and conversion, EuroOptic’s new site showcases the power of the full Commerce portfolio of BigCommerce, Feedonomics and Makeswift

Collaboration launches Hope Estates, a 38-unit supportive housing development serving foster youth, seniors and families in Kansas

Family donations over a decade inspired by loved one’s life-saving transplant helped NMDP surpass $100 million campaign goal

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about December 18, 2025, subject to the satisfaction of customary closing conditions.

Atlanta, GA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI),  a technology company focused on advanced AI-powered security screening solutions, today provided an update on the actions it has taken in recent months as part of its ongoing efforts to address Nasdaq listing requirements.

TORONTO , Dec. 15, 2025 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today that, in connection with its ongoing substantial issuer bid (the “SIB”) to purchase for cancellation up to C$350,000,000 in value of its common shares (the “Shares”), the Ontario Securities Commission (the “OSC”), as Altus Group’s principal regulator, has granted an exemptive relief order exempting Altus Group from complying with certain extension take up, proportionate take up and related disclosure requirements.

Management to discuss multiple B2B partnerships

HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 5,227,275 shares of common stock at an exercise price of $0.33 per share. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the Company's stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants (the “Stockholder Approval”) and will expire five years following the date of the Stockholder Approval. The closing of the offering is expected to occur on or about December 16, 2025, subject to the satisfaction of customary closing conditions.

AUSTIN, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FTC Solar, Inc. (Nasdaq: FTCI), a leading global provider of solar tracker systems, software, and engineering services, today announced the appointment of Anthony Carroll to its Board of Directors, effective December 15, 2025.

Highlights: 

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis

Deal Expands AssetMark’s RIA Footprint, Adds $3 Billion in Client Assets, and Unlocks New Value for Advisors

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) --  NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical, automotive and consumer electronics industries, with operations across Asia and partnerships around the globe. The investment was led by Checkmate Capital, a strategic advisory and investment group headquartered in Pasadena, California. The investment and manufacturing project are part of a collaboration between Armstrong and Checkmate, stemming from their July 2025 strategic memorandum of understanding (MOU) focused on the development and manufacturing of new technologies, particularly in the medical device industry.

Datavault AI’s International Name, Image and Likeness (“NIL”) Exchange will Solve for Regulatory Compliant with Quantum Encrypted Smart Contracts that will Present the Winning Solution

zerohash introduces the first-of-its-kind children’s book as stablecoin transactions hit historic milestones.

HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HyOrc Corporation (OTCID: HYOR), an SEC-reporting clean-energy company focused on decarbonizing heavy industry, today highlighted the relevance of its U.S. rail initiatives amid increasing scrutiny of emissions from legacy freight rail operations.

CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2025 and are reported in U.S. Dollars under GAAP.

BEVERLY HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Green Rain Energy Holdings Inc. (OTCID: GREH) (“Green Rain” or the “Company”) today announced that its management team and board of directors extend their sincere holiday wishes to all shareholders, partners, and stakeholders.

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026

Removes Key Adoption Barriers in Pediatric/Adolescent Oncology and Deformity Market

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical countermeasures. DRDC is evaluating pharmacological compounds, including Bucillamine, that may mitigate nerve agent–induced brain injury.

Globally renowned executive in betting, gaming, and fintech boasts track record of driving innovation, digital transformation, and international growth  

Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen

Vancouver, BC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce the appointment of Paul Kremer as Exploration Manager working alongside the existing geological team led by VP Exploration, Cornell McDowell. The Board of Directors and Management enthusiastically welcome Mr. Kremer to the team as Trident accelerates its exploration programs across Saskatchewan’s highly prospective gold belts.

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficiency for the Company.

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions.

CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced that it has entered into a definitive agreement (the “Arrangement Agreement”) pursuant to which a special purpose acquisition vehicle (the “Purchaser”), to be funded by affiliates of each of Kingswood Capital Management, L.P. (“Kingswood”) and Forager Capital Management, LLC (“Forager”), solely to effect the acquisition of Quipt, will acquire, in an all cash transaction, all of the issued and outstanding common shares in the capital of Quipt (the “Shares”) for US$3.65 per share.